Article metrics

Download PDFPDF

451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

 

Online download statistics by month:

Online download statistics by month: November 2020 to May 2022

AbstractFullPdf
Nov 2020223025
Dec 20203607
Jan 20213406
Feb 20211602
Mar 20213004
Apr 20214804
May 2021001
Jun 2021007
Jul 2021008
Aug 2021006
Sep 2021007
Oct 202136025
Nov 202176022
Dec 20217403
Jan 20222003
Feb 20223603
Mar 20225406
Apr 20225008
May 20223401
Total7670148